Radical Numerics Launches Omnii-1, a New Generation of Biological AI, as First AI-Designed Phage Therapy Reaches Human Patient

Built by the team behind Evo and Evo 2, Omnii-1 is the largest multimodal genome language model ever built, capable of understanding and designing biology to advance new medicines, disease detection and biodefense

SAN FRANCISCO, October 20, 2026--Radical Numerics, an AI research lab building general biological intelligence, today launched Omnii-1, a biological AI model that learns across DNA, RNA, proteins and other molecular data. Researchers used Omnii to design a bacteriophage and administered it to a patient with a drug-resistant bacterial infection, marking the first AI-designed phage given to a human patient.

Omnii-1 is a genome language model built on the same AI technology behind large language models, but trained on biological data instead of human language. Radical Numerics developed a way to convert 28 types of biological data, including DNA, RNA, proteins and epigenetic signals, into a common representation that AI can learn from. At launch, the company is demonstrating Omnii across eight applications, including personalized cancer vaccine design, identifying the genetic causes of rare diseases and detecting emerging biological threats.

From AI-generated DNA to a human patient

Radical Numerics was founded by members of the team behind Evo and Evo 2, models used to design the first bacteriophage genomes created entirely by AI. The research, first reported in August 2026, helped establish that AI could go beyond reading the genetic code to writing new biological systems.

Drug-resistant infections were linked to an estimated 4.95 million deaths worldwide in 2019, including 1.27 million directly attributable to antimicrobial resistance. For patients whose infections no longer respond to antibiotics, few options remain. One alternative is bacteriophages, viruses that kill bacteria. But finding a phage that works against a particular patient's infection can take months and often fails. Omnii offers a different approach: instead of searching for the right virus, design one.

In a recent case, researchers used Omnii to design phages targeting the patient's persistent drug-resistant infection within weeks. A cocktail containing an AI-designed phage killed the patient's bacterial isolate in laboratory testing and was then administered at a clinical site under a physician compassionate use access.

"For most of medicine's history, we've searched for drugs that might work against a disease. We're entering a future where we can design medicines for the exact biology of a patient," said Eric Nguyen, co-founder and CEO of Radical Numerics. "But we didn't build Omnii for any single application. We designed it to be a general-purpose AI model that can learn to tackle virtually any task in biology. The phage reaching a patient is one of the first examples of what that approach can make possible."